Stem and Progenitor Cells Isolated from Cord Blood

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cord blood (CB) has now been used to treat more than 25,000 patients with malignant and non-malignant disorders in a setting of hematopoietic stem cell (HSC) transplantation. These have taken all place since the first CB transplant occurred in October 1988 in Paris, France with cells tested and frozen in my laboratory and hand-delivered to Paris. While there are advantages to using CB as a source of HSCs, the disadvantages include slower time to neutrophil, platelet, and immune cell recovery. This chapter reviews recent efforts to enhance the engrafting capability of CB cells through double CB transplantation, and methods to enhance the homing and engraftment of the limited number of cells present in a single CB transplantation. The length of time CB has been cryopreserved form and efficiently recovered with functional capability is now more than 23 years. Retrieved CB cells are also capable of generating induced pluripotent stem cells and endothelial colony-forming cells of high proliferative activity. Efforts to make CB a more efficient and efficacious source of transplantable cells continue.

Original languageEnglish
Title of host publicationEssentials of Stem Cell Biology: Third Edition
PublisherElsevier Inc.
Pages157-161
Number of pages5
ISBN (Print)9780124104273, 9780124095038
DOIs
StatePublished - Nov 4 2013

Fingerprint

Fetal Blood
Stem Cells
Paris
Blood Cells
Transplantation
Induced Pluripotent Stem Cells
Hematopoietic Stem Cell Transplantation
France
Neutrophils
Blood Platelets
Hand
Cell Count
Transplants

Keywords

  • Cord blood
  • Cryopreservation
  • Engraftment
  • Graft failure
  • Graft versus host disease
  • Hematopoietic stem cell transplant
  • HLA typing
  • Induced pluripotent stem cells

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Broxmeyer, H. (2013). Stem and Progenitor Cells Isolated from Cord Blood. In Essentials of Stem Cell Biology: Third Edition (pp. 157-161). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-409503-8.00012-3

Stem and Progenitor Cells Isolated from Cord Blood. / Broxmeyer, Hal.

Essentials of Stem Cell Biology: Third Edition. Elsevier Inc., 2013. p. 157-161.

Research output: Chapter in Book/Report/Conference proceedingChapter

Broxmeyer, H 2013, Stem and Progenitor Cells Isolated from Cord Blood. in Essentials of Stem Cell Biology: Third Edition. Elsevier Inc., pp. 157-161. https://doi.org/10.1016/B978-0-12-409503-8.00012-3
Broxmeyer H. Stem and Progenitor Cells Isolated from Cord Blood. In Essentials of Stem Cell Biology: Third Edition. Elsevier Inc. 2013. p. 157-161 https://doi.org/10.1016/B978-0-12-409503-8.00012-3
Broxmeyer, Hal. / Stem and Progenitor Cells Isolated from Cord Blood. Essentials of Stem Cell Biology: Third Edition. Elsevier Inc., 2013. pp. 157-161
@inbook{f5b73ca752bb42f2a5ccc8f737bc56a5,
title = "Stem and Progenitor Cells Isolated from Cord Blood",
abstract = "Cord blood (CB) has now been used to treat more than 25,000 patients with malignant and non-malignant disorders in a setting of hematopoietic stem cell (HSC) transplantation. These have taken all place since the first CB transplant occurred in October 1988 in Paris, France with cells tested and frozen in my laboratory and hand-delivered to Paris. While there are advantages to using CB as a source of HSCs, the disadvantages include slower time to neutrophil, platelet, and immune cell recovery. This chapter reviews recent efforts to enhance the engrafting capability of CB cells through double CB transplantation, and methods to enhance the homing and engraftment of the limited number of cells present in a single CB transplantation. The length of time CB has been cryopreserved form and efficiently recovered with functional capability is now more than 23 years. Retrieved CB cells are also capable of generating induced pluripotent stem cells and endothelial colony-forming cells of high proliferative activity. Efforts to make CB a more efficient and efficacious source of transplantable cells continue.",
keywords = "Cord blood, Cryopreservation, Engraftment, Graft failure, Graft versus host disease, Hematopoietic stem cell transplant, HLA typing, Induced pluripotent stem cells",
author = "Hal Broxmeyer",
year = "2013",
month = "11",
day = "4",
doi = "10.1016/B978-0-12-409503-8.00012-3",
language = "English",
isbn = "9780124104273",
pages = "157--161",
booktitle = "Essentials of Stem Cell Biology: Third Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Stem and Progenitor Cells Isolated from Cord Blood

AU - Broxmeyer, Hal

PY - 2013/11/4

Y1 - 2013/11/4

N2 - Cord blood (CB) has now been used to treat more than 25,000 patients with malignant and non-malignant disorders in a setting of hematopoietic stem cell (HSC) transplantation. These have taken all place since the first CB transplant occurred in October 1988 in Paris, France with cells tested and frozen in my laboratory and hand-delivered to Paris. While there are advantages to using CB as a source of HSCs, the disadvantages include slower time to neutrophil, platelet, and immune cell recovery. This chapter reviews recent efforts to enhance the engrafting capability of CB cells through double CB transplantation, and methods to enhance the homing and engraftment of the limited number of cells present in a single CB transplantation. The length of time CB has been cryopreserved form and efficiently recovered with functional capability is now more than 23 years. Retrieved CB cells are also capable of generating induced pluripotent stem cells and endothelial colony-forming cells of high proliferative activity. Efforts to make CB a more efficient and efficacious source of transplantable cells continue.

AB - Cord blood (CB) has now been used to treat more than 25,000 patients with malignant and non-malignant disorders in a setting of hematopoietic stem cell (HSC) transplantation. These have taken all place since the first CB transplant occurred in October 1988 in Paris, France with cells tested and frozen in my laboratory and hand-delivered to Paris. While there are advantages to using CB as a source of HSCs, the disadvantages include slower time to neutrophil, platelet, and immune cell recovery. This chapter reviews recent efforts to enhance the engrafting capability of CB cells through double CB transplantation, and methods to enhance the homing and engraftment of the limited number of cells present in a single CB transplantation. The length of time CB has been cryopreserved form and efficiently recovered with functional capability is now more than 23 years. Retrieved CB cells are also capable of generating induced pluripotent stem cells and endothelial colony-forming cells of high proliferative activity. Efforts to make CB a more efficient and efficacious source of transplantable cells continue.

KW - Cord blood

KW - Cryopreservation

KW - Engraftment

KW - Graft failure

KW - Graft versus host disease

KW - Hematopoietic stem cell transplant

KW - HLA typing

KW - Induced pluripotent stem cells

UR - http://www.scopus.com/inward/record.url?scp=84942759218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942759218&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-409503-8.00012-3

DO - 10.1016/B978-0-12-409503-8.00012-3

M3 - Chapter

AN - SCOPUS:84942759218

SN - 9780124104273

SN - 9780124095038

SP - 157

EP - 161

BT - Essentials of Stem Cell Biology: Third Edition

PB - Elsevier Inc.

ER -